|
|
| Solving The DNA Knock-In Problem | Article | Applied StemCell | An in‑depth exploration of why large, precise DNA knock‑ins limit cell therapy progress—and how site‑specific integration enables durable, scalable genetic engineering solutions. |
|
|
|
|
|
|
By Jeffrey S. Buguliskis, Ph.D., Deputy Chief Editor, Outsourced Pharma | Over two days in Boston, biopharma leaders at CDMO Live Americas confronted a blunt truth: the outsourcing sector doesn't lack ambition or stainless steel, it has a widening gap between partnership intent and shop-floor delivery. | |
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | A number of patients report receiving half a pill in a blister pack of their prescribed medicine. The initial sponsor reaction is to place the problem at an external partner’s production or packaging line. But overall responsibility lies with the sponsor, and the true extent of the problem is hard to detect. Enter AI. Experienced pharma quality expert Damiano Dragone believes AI combined with professionals throughout the supply chain can join in a new “logic and creativity" to improve our industry on behalf of patients. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| Overcoming Lentiviral Vector Challenges | Article | By Vijetha Bhat, Wenling Dong, and F. Michael Haller, Ph.D., Lonza | Lentiviral vector fragility and the lack of tools to separate full from empty particles complicate downstream processing, while analytics and manufacturing expertise change how developers respond. |
|
|
|
|
| What FDA CRLs Reveal About Cell-Based Potency Assays | White Paper | Solvias | Cell-based potency assays are critical for defining drug quality, yet frequent FDA CRLs cite assay deficiencies. Learn key pitfalls and strategies to strengthen validation and regulatory readiness. |
|
|
| Vial Containment Systems For Gene Therapies | E-Book | By Margaret A. Craig, Rui Li, and T. Page McAndrew, West Pharmaceutical Services, Inc. | Research across AAV, adenovirus, and lentivirus vectors shows cyclic olefin polymer vial systems match or outperform borosilicate glass on viral vector recovery and container closure integrity. |
|
|
|
|
| Balancing Early-Stage Needs With Future Success | Article | By Omar Baez, Comprehensive Cell Solutions | Streamlining the tech transfer process is a key variable in shortening development timelines and controlling costs, maximizing a molecule's potential for late-stage success. |
|
|
| Using Rapid Development To Accelerate CGT Development | Webinar | Thermo Fisher Scientific | Assimilate how the following framework can accelerate your viral vector, CAR-T, and iPSC programs, reduce risk, and streamline your path from development to commercial manufacturing. |
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|